Anti-DRAM1 [M3-P4B4]

DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.

Contributors

Inventor Institute
Ayham Alnabulsi Vertebrate Antibodies Limited
Cat. #: 151871
Tool sub type: Primary antibody
Unit size: 100 ug
Cancer types: Colorectal cancer
Research Fields: Apoptosis and autophagy;Cancer;Cell biology;Cell signaling and signal transduction;Metabolism;Tissue-specific biology
Application: ELISA ; IHC ; IF ; WB
Target: Damage Regulated Autophagy Modulator 1 (DRAM1)
Reactivity: Human
Clone: M3-P4B4
Host: Mouse
Class: Monoclonal
Product description: DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.
Conjugation: Unconjugated
Isotype: IgG1
Immunogen: Peptide Sequence – EKDYVYHVVS (amino acids 192 – 201)
Myeloma used: P3X63Ag8.653
Target background: DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.
Format: Liquid
Concentration: 0.9-1.1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.

The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151029 Anti-HSVICP8 [11E2] Key Info View Tool
151034 Anti-HSVUL42 [13D11] Key Info View Tool
151040 Anti-CD11 & CD18 [24] Key Info View Tool
151017 Anti-MBP [R29.6] Key Info View Tool
151035 Anti-CD8 [14] mAb Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.